GlassScriptPhysician profile
Arif Habib
NPI 1215912977
$5,538.09
in general payments reported to CMS, 2019-2025
18 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,771 · 2020: $277 · 2021: $257 · 2022: $41.74 · 2023: $19.78 · 2024: $67.75 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.89 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $4,359.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $281.68 | 2019-2024 | Invega Sustenna |
| Abbvie INC. | $159.46 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.76 | 2019-2020 | |
| Alkermes, INC. | $92.95 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $86.52 | 2019-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $71.54 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.82 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.31 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $50.49 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.94 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $44.00 | 2019-2020 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Orexo US, INC. | $27.31 | 2020 | |
| Allergan, INC. | $24.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $21.76 | 2019 | |
| Indivior INC. | $13.26 | 2024 | Sublocade |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.